Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. The Dow Jones Industrial Average ( ^DJI) is trading up 103 points (+0.7%) at 13,983 as of Tuesday, Feb 5, 2013, 12:35 p.m. ET. During this time, 282.6 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 632.6 million. The NYSE advances/declines ratio sits at 2,059 issues advancing vs. 855 declining with 126 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be Merck (NYSE: MRK), which is sporting a 48-cent gain (+1.2%) bringing the stock to $41.34. This single gain is lifting the Dow Jones Industrial Average by 3.63 points or roughly accounting for 3.5% of the Dow's overall gain. Volume for Merck currently sits at 9.5 million shares traded vs. an average daily trading volume of 13.3 million shares. Merck has a market cap of $127.17 billion and is part of the health care sector and drugs industry. Shares are down 0.2% year to date as of Monday's close. The stock's dividend yield sits at 4.1%. Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company has a P/E ratio of 19, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.